Apellis Pharmaceuticals, Inc. (APLS)

NASDAQ: APLS · Real-Time Price · USD

20.96

-0.68 (-3.14%)

At close: Feb 27, 2026, 4:00 PM EST

20.80

-0.16 (-0.76%)

After-hours: Feb 27, 2026, 7:55 PM EST

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
EMPAVELI Revenue	102.45M	98.09M
EMPAVELI Revenue Growth	4.44%	7.75%
SYFOVRE Revenue	586.93M	611.86M
SYFOVRE Revenue Growth	-4.07%	122.30%
Total Product Revenue	689.38M	709.95M
Total Product Revenue Growth	-2.90%	93.83%
Licensing and Other Revenue	314.40M	71.41M
Licensing and Other Revenue Growth	340.25%	135.61%
Revenue (Total)	1.00B	781.37M
Revenue (Total) Growth	28.46%	97.02%

Updated Feb 24, 2026. Data Source: Fiscal.ai.